Clinical Trial Update: Bortezomib in Late Antibody-mediated Kidney Transplant Rejection [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating bortezomib for late antibody-mediated rejection in renal transplant recipients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Antibody-mediated Rejection of Kidney Transplant
• Kidney Transplant Rejection

Drugs mentioned

• Velcade (bortezomib) (bortezomib)

Snippet

Sponsor: Medical University of Vienna | Conditions: Late Rejection of Renal Transplant, Antibody-mediated Rejection | Phase 2 | Status: COMPLETED